Products for Research Use Only

Ursocholic acid-d4

CAT: 0804-HY-113212SSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-113212SSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ursocholic acid-d4 is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis[1][2][3][4][5][6].
UNSPSC
12352211
Target
Apoptosis; Endogenous Metabolite; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Smiles
O[C@@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](CC3)([H])[C@H](C)CCC(O)=O)([C@H](C[C@]2([H])[C@@]4([C@](C([2H])([2H])[C@@H](C([2H])([2H])C4)O)([H])C1)C)O)C
Molecular Formula
C24H36D4O5
Molecular Weight
412.60
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Ikegami, et al. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatology Research 38.2 (2008) : 123-131.|[3]MacDonald IA, et al. Formation of ursodeoxycholic acid from chenodeoxycholic acid by a 7 beta-hydroxysteroid dehydrogenase-elaborating Eubacterium aerofaciens strain cocultured with 7 alpha-hydroxysteroid dehydrogenase-elaborating organisms. Appl Environ Microbiol. 1982 Nov;44 (5) :1187-95.|[4]Kim, et al. Ursodeoxycholic acid attenuates 5‑fluorouracil‑induced mucositis in a rat model. Oncology letters 16.2 (2018) : 2585-2590.|[5]Lee HI, et al. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. Int J Clin Pharmacol Ther. 2014 Nov;52 (11) :981-5.|[6]Dubreuil, et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver international 33.7 (2013) : 1029-1038.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported